This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Exact Sciences

BOSTON ( TheStreet) -- Friday's Biotech Stock Mailbag kicks off with an email from Ted S. concerning Exact Sciences (EXAS - Get Report) and its genetic screening test for colon cancer.

"Last Friday (July 16) on a conference call, Exact Sciences said it would release their external validation results for their genetic screening test for colon cancer by Oct. 29. What percent of pre-cancers and what percent of cancers do you believe need to be detected by the validation study for it to be perceived as a positive for Exact Sciences? Also, how big of an event do you believe this is for Exact Sciences?"

These study results are a very big deal for Exact because this will be the first validation data we see that measures the sensitivity of the company's colon cancer test, which is designed to detect small changes in DNA found in stool. These genetic mutations can be a warning sign of early-stage cancer or even of pre-cancerous polyps, in the colon.

Based on previous guidance, Exact is shooting for its test to be sensitive enough to detect about 85% of colon cancers and 50% of pre-cancerous lesions. That would put the company's test ahead of currently used fecal blood tests but less sensitive than colonoscopy -- by design.

Exact expects to announce data from the three validation studies on Oct. 29 at the American Association of Cancer Research meeting in Philadelphia. These data are very important, but they don't get Exact to the finish line. None of samples being tested are being tested prospectively, which means Exact will still need data from a large, pivotal phase III study before it can seek FDA approval. Exact plans to run that phase III study starting in the second half of 2011, with the FDA filing set for 2012.

I met with Exact's CEO Kevin Conroy at the J.P. Morgan Healthcare Conference in January and walked away impressed. At that time, I called Exact Sciences the "best small-cap story" at the conference during the busy week in San Francisco. The stock was trading just above $4 at that time. Today, shares can be bought for less than $3.50, so my hot stock pick hasn't exactly worked out that well.

I'm hoping that changes when the validation data are revealed on Oct. 29.

Mannkind (MNKD) announced Tuesday that the FDA accepted the company's resubmission of the approval application for its Afrezza inhaled insulin device. The agency's new approval decision deadline is Dec. 29.

The Afrezza update prompted @RJPeterson123 to tweet, "Hoping for a Christmas miracle for Mannkind."
1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CTIC $1.63 -0.61%
EXAS $7.93 -3.80%
GILD $98.81 -0.70%
JNJ $95.89 -0.10%
MNKD $3.06 0.49%


Chart of I:DJI
DOW 17,105.38 -26.48 -0.15%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,839.59 +0.9470 0.02%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs